Principal Financial Group
ADPT icon

Principal Financial Group’s Adaptive Biotechnologies ADPT Stock Holding History

Principal Financial Group’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$833K Sell
38,829
-1,666,058
-98% -$25.5M ﹤0.01% 1966
2026
Q1 		$23.7M Buy
1,704,887
+152,378
+10% +$2.43M 0.01% 827
2025
Q4 		$25.2M Buy
1,552,509
+944,167
+155% +$15.4M 0.01% 758
2025
Q3 		$9.1M Sell
608,342
-303,285
-33% -$3.7M ﹤0.01% 1337
2025
Q2 		$10.6M Buy
911,627
+626,492
+220% +$5.69M 0.01% 1233
2025
Q1 		$2.12M Buy
285,135
+141,691
+99% +$1.09M ﹤0.01% 1759
2024
Q4 		$860K Buy
+143,444
New +$791K ﹤0.01% 1892
2024
Q3 		– Sell
-17,495
Closed -$63.3K – 2225
2024
Q2 		$63.3K Sell
17,495
-15,009
-46% -$47.6K ﹤0.01% 2262
2024
Q1 		$104K Sell
32,504
-459,615
-93% -$1.78M ﹤0.01% 2269
2023
Q4 		$2.41M Sell
492,119
-754,745
-61% -$3.44M ﹤0.01% 1748
2023
Q3 		$6.8M Sell
1,246,864
-8,259
-0.7% -$54.6K ﹤0.01% 1413
2023
Q2 		$8.42M Buy
1,255,123
+7,992
+0.6% +$59.4K 0.01% 1333
2023
Q1 		$11M Sell
1,247,131
-9,780
-0.8% -$86.2K 0.01% 1206
2022
Q4 		$9.6M Sell
1,256,911
-57,368
-4% -$446K 0.01% 1256
2022
Q3 		$9.36M Buy
1,314,279
+113,217
+9% +$1.07M 0.01% 1222
2022
Q2 		$9.72M Buy
1,201,062
+685,171
+133% +$6.02M 0.01% 1273
2022
Q1 		$7.16M Buy
515,891
+34,064
+7% +$536K ﹤0.01% 1521
2021
Q4 		$13.5M Buy
481,827
+8,059
+2% +$247K 0.01% 1228
2021
Q3 		$16.1M Buy
473,768
+12,059
+3% +$436K 0.01% 1108
2021
Q2 		$18.9M Buy
461,709
+109,380
+31% +$4.25M 0.01% 1023
2021
Q1 		$14.2M Buy
352,329
+29,042
+9% +$1.57M 0.01% 1187
2020
Q4 		$19.1M Buy
323,287
+6,213
+2% +$320K 0.01% 802
2020
Q3 		$15.4M Buy
317,074
+109,027
+52% +$4.58M 0.01% 803
2020
Q2 		$10.1M Buy
208,047
+138,977
+201% +$5.07M 0.01% 1052
2020
Q1 		$1.92M Sell
69,070
-4,800
-6% -$134K ﹤0.01% 1608
2019
Q4 		$2.21M Buy
73,870
+3,743
+5% +$107K ﹤0.01% 1711
2019
Q3 		$2.17M Sell
70,127
-9,873
-12% -$403K ﹤0.01% 1706
2019
Q2 		$3.86M Buy
+80,000
New +$3.54M ﹤0.01% 1602

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Principal Financial Group's ADPT Position: Q2 2026 in Review

Principal Financial Group reduced its Adaptive Biotechnologies (ADPT) stake by 98% in Q2 2026, selling an estimated $25.5M and leaving 38,829 shares worth $833K. The position accounts for ﹤0.01% of the portfolio, ranked #1966.

Principal Financial Group first reported a position in ADPT in Q2 2019 and has held it in 28 quarters since. The position peaked at $25.2M in Q4 2025. 300 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • Principal Financial Group held 38,829 shares of Adaptive Biotechnologies worth $833K as of Q2 2026.
  • Principal Financial Group sold 1,666,058 Adaptive Biotechnologies shares in Q2 2026, an estimated $25.5M.
  • Adaptive Biotechnologies made up ﹤0.01% of Principal Financial Group's portfolio in Q2 2026, its #1966 holding.
  • Principal Financial Group first reported a position in Adaptive Biotechnologies in Q2 2019 and has held it in 28 quarters since.
  • Principal Financial Group's Adaptive Biotechnologies position peaked at $25.2M in Q4 2025.
  • 300 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Principal Financial Group's 13F filing for Q2 2026, filed 4 Aug 2026.